Fosun Pharma shareholders approve share schemes, key agreements at EGM

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that all resolutions proposed at its 2025 First Extraordinary General Meeting (EGM) on October 23, 2025, were duly passed. Key special resolutions, including the adoption of the 2025 A Share Option Scheme and the 2025 H Share RSU Scheme, each received overwhelming support, with over 99% of votes cast in favor. The mandate to the board to deal with matters pertaining to these schemes also passed with similar strong majorities.

Ordinary resolutions for the grant of RSUs to executive directors also passed, with Chen Yuqing receiving 953,500 RSUs (95.9416% for), Guan Xiaohui 686,500 RSUs (95.9661% for), and Liu Yi 762,800 RSUs (95.9265% for). Additionally, the Renewed Financial Services Agreement dated August 26, 2025, and the Renewed Products/Services Mutual Supply Framework Agreement, also dated August 26, 2025, were approved with 94.3981% and 99.7740% of votes in favor, respectively.

The EGM saw 1,640 shareholders and authorized proxies attend, representing 1,100,625,377 shares, or 41.6974% of total voting rights. Directors and related parties abstained from voting on resolutions where they had a material interest, ensuring compliance with Hong Kong Listing Rules.